The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea.
J Korean Med Sci
; 37(14): e107, 2022 Apr 11.
Article
in En
| MEDLINE
| ID: mdl-35411727
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Tuberculosis
/
Inflammatory Bowel Diseases
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
J Korean Med Sci
Journal subject:
MEDICINA
Year:
2022
Type:
Article